$LQDA

Krepp Sarah sold $562K of LQDA

Krepp Sarah (Chief Human Resource Officer) sold 7,864 shares of Liquidia Corp (LQDA) at an average of $71.51 ($71.39–$71.52, $0.56M total) across 2 trades on 2026-07-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Krepp Sarah
Published Jul 15, 2026, 12:11 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 15, 2026, 12:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$LQDA
Neutral
high confidence
Mentioned
$LQDA
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

The newest fact is the specific open-market sale size, price range, and confirmation that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note the sale for sentiment monitoring, but it is unlikely to change valuation without accompanying fundamental news.

03

What to watch

The disclosure does not state motives; 10b5-1 sales are often scheduled for diversification or liquidity, reducing interpretability versus unscheduled sales.

Relevance 4/10Novelty 3/10Timing: Filed July 14 after July 13 insider sale execution.

Background

The article is an SEC Form 4 insider transaction report for Liquidia Corp, filed the day after the trades.

Company-level read

Ticker impact

$LQDANeutralHigh confidence
Context

Liquidia insider Krepp Sarah, Chief Human Resource Officer, sold 7,864 shares in open-market trades under a 10b5-1 plan on July 13.

Expected impact

Limited near-term impact; any effect is likely sentiment-only and typically fades unless paired with other news.

Evidence & confidence

The filing is a Form 4 insider transaction with a pre-arranged 10b5-1 plan, and it does not include new company fundamentals, guidance, or regulatory/clinical developments.

Market effects

No clear sector read-through from a single HR officer’s 10b5-1 sale.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still be interpreted as confidence erosion by some traders, especially if it coincides with other negative signals not mentioned here.

Key entities

  • Liquidia Corp

    Company whose insider transaction is disclosed on Form 4.

  • Krepp Sarah

    Chief Human Resource Officer who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?

Liquidia Corporation (LQDA) is relying on Yutrepia, its inhaled dry-powder treprostinil therapy, to drive growth despite intense competition in the PAH market. Yutrepia generated $300.3M in sales in H1 2026 and has seen strong adoption. LQDA faces competition from United Therapeutics (UTHR) and Insmed (INSM), with UTHR expanding its PAH franchise. LQDA's shares have surged 96.3% YTD, trading at 6.16X forward sales. Analysts have lowered EPS estimates for 2026 and 2027.

$LQDAHighAI 8/10

Liquidia (LQDA) Q2 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q2 2026 earnings with YUTREPIA net sales at $170.4M, up 31% QoQ. Net income was $74.7M ($0.74/diluted share). The company guided 2027 revenue to exceed $1B. R&D expenses rose 185% YoY due to L606 program costs. Management highlighted strong patient adoption and market share growth.

$LQDAMedAI 8/10

LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth

Liquidia (LQDA) reported Q2 2026 EPS of 74 cents, above the Zacks estimate of 70 cents. Revenues rose to $171.7 million from $8.8 million a year earlier, beating the $165 million consensus, driven by Yutrepia net product sales of $170.4 million. Shares fell about 10% after results. Liquidia said it targets over $1 billion net revenues in 2027.

$LQDAMed

Liquidia Corp (LQDA): Results of Operations and Financial Condition

Liquidia Corp (LQDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Liquidia Corporation Reports Second Quarter 2026 Financial Results · YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $170.4 million in the second quarter of 2026, up 31% from the first quarter of 2026 · Approximately 5,900 unique patient